Cutera(CUTR) - 2022 Q3 - Quarterly Report

Financial Performance - Total net revenue for Q3 2022 was $62,808,000, a 9% increase from $57,384,000 in Q3 2021[19] - Product revenue reached $56,540,000 in Q3 2022, up from $50,694,000 in Q3 2021, representing an increase of 11%[19] - Gross profit for Q3 2022 was $34,248,000, compared to $33,425,000 in Q3 2021, indicating a slight increase of 2%[19] - The net loss for Q3 2022 was $12,134,000, compared to a net loss of $1,390,000 in Q3 2021, marking a significant increase in losses[19] - The company reported a basic net loss per share of $0.62 for Q3 2022, compared to a loss of $0.08 per share in Q3 2021[19] - The net loss for the nine months ended September 30, 2022, was $74,552, compared to a net income of $5,997 for the same period in 2021[36] - The total stock-based compensation expense for the three months ended September 30, 2022, was $4.245 million, up from $3.742 million in the same period of 2021[105] - The Company recognized an income tax expense of $0.8 million for the three months ended September 30, 2022, compared to $0.5 million for the same period in 2021[114] Expenses and Liabilities - Total operating expenses increased to $43,681,000 in Q3 2022 from $32,799,000 in Q3 2021, reflecting a 33% rise[19] - Cash used in operating activities for the nine months ended September 30, 2022, was $49,968, compared to $1,428 for the same period in 2021[36] - The total accrued liabilities decreased to $50.8 million as of September 30, 2022, compared to $54.1 million as of December 31, 2021, with notable reductions in bonus and payroll-related accruals[76] - The company had accrued $0.6 million related to various pending lawsuits as of September 30, 2022[131] Assets and Cash Flow - Cash and cash equivalents decreased to $45,880,000 as of September 30, 2022, down from $164,164,000 at the end of 2021[14] - Total current assets increased to $366,312,000 as of September 30, 2022, compared to $249,661,000 at the end of 2021, a growth of 47%[14] - The total stockholders' equity as of September 30, 2022, was $15,494, down from $56,569 as of December 31, 2021[36] - The cash, cash equivalents, and restricted cash at the end of the period were $46,580, down from $164,864 at the beginning of the period[36] - As of September 30, 2022, total cash equivalents and marketable investments amounted to $205.9 million, with $960,000 in money market funds and $204.9 million in available-for-sale securities[67] Revenue Sources - Revenue from performance obligations satisfied over time accounted for approximately 8% of total revenue for the three months ended September 30, 2022, compared to 12% for the same period in 2021[83] - The Company’s revenue from systems for the nine months ended September 30, 2022, was $121.2 million, a 26.2% increase from $96.1 million in the same period of 2021[176] - Revenue from the United States for the three months ended September 30, 2022, was $28.1 million, up 23.3% from $22.7 million in the same period of 2021[176] Product Development and Market Strategy - Cutera received 510(k) clearance from the U.S. FDA for its AviClear acne treatment device in March 2022, with a full commercial launch expected by the end of the current calendar year[40] - The Company introduced the AviClear acne treatment device in April 2022, which is expected to have a full commercial launch by the end of the current calendar year[190] - The Company believes its revenue growth will depend on the successful commercialization of AviClear and expansion of product offerings[194] - The Company’s ongoing research and development activities focus on developing new products and enhancing existing products[185] Market Conditions and Risks - Risks affecting future operations include rapid technological change, competition, and potential impacts from inflation and economic instability[43][46] - The Company is experiencing a challenging inflationary environment, leading to tighter household budgets and reduced spending on aesthetic treatments, which may negatively impact product demand and revenue[201] - The future growth of skincare product sales is contingent on customers maintaining their pandemic-era spending habits; a reversion could materially affect revenue and cash flows[203] Debt and Financing - The outstanding principal amount of convertible notes due in 2026 was $69,125,000 as of September 30, 2022, down from $138,250,000 in December 2021[133] - The Company issued $240 million in convertible notes due in 2028 in May 2022, with an initial conversion price of approximately $52.67 per share[136] - The effective interest rates on the 2026 Notes and 2028 Notes are 2.98% and 2.82%, respectively[165] - The Company entered into a Loan and Security Agreement with Silicon Valley Bank for a secured revolving loan facility of up to $30.0 million, maturing on July 9, 2024[166] - As of September 30, 2022, the Company had not drawn on the SVB Revolving Line of Credit and is in compliance with all financial covenants[171]